Ramatroban

Ramatroban
Clinical data
Trade names	Baynas
AHFS/Drugs	International Drug Names
Routes of; administration	Oral (tablets)
ATC code	None;
Legal status
Legal status	Rx-only(JP);
Identifiers
	IUPAC name 3-((3R)-3-{[(4-fluorophenyl)sulfonyl]amino}-1,2,3,4-tetrahydro-9H-carbazol-9-yl)propanoic acid;
CAS Number	116649-85-5;
PubChemCID	123879;
IUPHAR/BPS	1910;
ChemSpider	110413;
UNII	P1ALI72U6C;
KEGG	D01128;
ChEMBL	ChEMBL361812;
CompTox Dashboard(EPA)	DTXSID1046685;
ECHA InfoCard	100.159.668
Chemical and physical data
Formula	C21H21FN2O4S
Molar mass	416.47g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1CC2=C(CC1NS(=O)(=O)C3=CC=C(C=C3)F)C4=CC=CC=C4N2CCC(=O)O;
	InChI InChI=1S/C21H21FN2O4S/c22-14-5-8-16(9-6-14)29(27,28)23-15-7-10-20-18(13-15)17-3-1-2-4-19(17)24(20)12-11-21(25)26/h1-6,8-9,15,23H,7,10-13H2,(H,25,26)/t15-/m1/s1; Key:LDXDSHIEDAPSSA-OAHLLOKOSA-N;

Ramatroban(INN) (also known asBAY u3405)^[1]is athromboxane receptor antagonist.^[2]

It is also aDP₂receptor antagonist.^[3]

It is indicated for the treatment ofcoronary artery disease.^[4]It has also been used for the treatment ofasthma.^[5]

It has been suggested that ramatroban, by modulatingDP₂receptor,can reverse viremia-associated proinflammatory and prothrombotic processes which are similar to those induced bySARS-Cov-2.^{[citation needed]}Hence, ramatroban, that has been used for the treatment of allergic rhinitis in Japan for the past two decades with a well established safety profile, merits investigation as a novel immunotherapy for the treatment ofCOVID-19disease, although no clinical trial has yet been conducted.^[6]

Ramatroban was developed by the German pharmaceutical companyBayer AGand is co-marketed inJapanby Bayer Yakuhin then marketed by Kyorin Pharmaceutical and Nippon Shinyaku Co., Ltd. under the trade nameBaynas.

References

^"Ramatroban (compound)".PubChem.National Center for Biotechnology Information.Retrieved22 June2019.
^Sugimoto H, Shichijo M, Iino T, Manabe Y, Watanabe A, Shimazaki M, et al. (April 2003). "An orally bioavailable small molecule antagonist of CRTH2, ramatroban (BAY u3405), inhibits prostaglandin D2-induced eosinophil migration in vitro".The Journal of Pharmacology and Experimental Therapeutics.305(1): 347–352.doi:10.1124/jpet.102.046748.PMID 12649388.S2CID 10016709.
^Royer JF, Schratl P, Carrillo JJ, Jupp R, Barker J, Weyman-Jones C, et al. (September 2008)."A novel antagonist of prostaglandin D2 blocks the locomotion of eosinophils and basophils".European Journal of Clinical Investigation.38(9): 663–671.doi:10.1111/j.1365-2362.2008.01989.x.PMID 18837743.
^Fiedler VB, Seuter F, Perzborn E (December 1990)."Effects of the novel thromboxane antagonist Bay U 3405 on experimental coronary artery disease"(PDF).Stroke.21(12 Suppl): IV149–IV151.PMID 2260140.
^Endo S, Akiyama K (November 1996). "[Thromboxane A2 receptor antagonist in asthma therapy]".Nihon Rinsho. Japanese Journal of Clinical Medicine(in Japanese).54(11): 3045–3048.PMID 8950952.
^Rizk JG, Kalantar-Zadeh K, Mehra MR, Lavie CJ, Rizk Y, Forthal DN (September 2020)."Pharmaco-Immunomodulatory Therapy in COVID-19".Drugs.80(13): 1267–1292.doi:10.1007/s40265-020-01367-z.PMC7372203.PMID 32696108.

External links

(in Japanese)Baynas Tablets Prescribing Information

Thisdrugarticle relating to therespiratory systemis astub.You can help Wikipedia byexpanding it.

Thisdrugarticle relating to thebloodandblood forming organsis astub.You can help Wikipedia byexpanding it.

[PubChem-1] "Ramatroban (compound)".PubChem.National Center for Biotechnology Information.Retrieved22 June2019.

[pmid12649388-2] Sugimoto H, Shichijo M, Iino T, Manabe Y, Watanabe A, Shimazaki M, et al. (April 2003). "An orally bioavailable small molecule antagonist of CRTH2, ramatroban (BAY u3405), inhibits prostaglandin D2-induced eosinophil migration in vitro".The Journal of Pharmacology and Experimental Therapeutics.305(1): 347–352.doi:10.1124/jpet.102.046748.PMID 12649388.S2CID 10016709.

[pmid18837743-3] Royer JF, Schratl P, Carrillo JJ, Jupp R, Barker J, Weyman-Jones C, et al. (September 2008)."A novel antagonist of prostaglandin D2 blocks the locomotion of eosinophils and basophils".European Journal of Clinical Investigation.38(9): 663–671.doi:10.1111/j.1365-2362.2008.01989.x.PMID 18837743.

[pmid2260140-4] Fiedler VB, Seuter F, Perzborn E (December 1990)."Effects of the novel thromboxane antagonist Bay U 3405 on experimental coronary artery disease"(PDF).Stroke.21(12 Suppl): IV149–IV151.PMID 2260140.

[pmid8950952-5] Endo S, Akiyama K (November 1996). "[Thromboxane A2 receptor antagonist in asthma therapy]".Nihon Rinsho. Japanese Journal of Clinical Medicine(in Japanese).54(11): 3045–3048.PMID 8950952.

[pmid32696108-6] Rizk JG, Kalantar-Zadeh K, Mehra MR, Lavie CJ, Rizk Y, Forthal DN (September 2020)."Pharmaco-Immunomodulatory Therapy in COVID-19".Drugs.80(13): 1267–1292.doi:10.1007/s40265-020-01367-z.PMC7372203.PMID 32696108.

[1]

[2]

[3]

[4]

[5]

[6]